CSI Market
Sign In | Register

Gilead Sciences Inc (GILD) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access GILD Annual Cash Flow →
The cash flow figures below highlight longer-term patterns in how Gilead Sciences Inc manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-8,475.00
Depreciation & amortization191.00
Amortization of Other Assets1,196.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)1,807.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories197.00
Research and Development in Process0.00
Sale of Assets0.00
Share-based Compensation449.00
Stockbased compensation0.00
Inprocess R & D0.00
Increase Decrease In Equity Securities Fv Ni-142.00
Research And Development Asset Acquired Other Than Through Business Combination Written Off107.00
Income taxes0.00
Losses/ -gains on investments net0.00
Accounts Receivable341.00
Increase (Decrease) in Accounts Payable-49.00
Increase (Decrease) in Accrued Liabilities-364.00
Deferred revenue0.00
Increase (Decrease) in Prepaid Expense and Other Assets8.00
Other Working Capital0.00
Other Noncash Income (Expense)-423.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities11,239.00
Discontinued operations0.00
Net Cash flow from Operating Activities6,117.00
Investing Activities
Capital Expenditures-257.00
Sale of Capital Items0.00
Short-term Investments Proceeds3,581.00
Payments to Acquire Available-for-sale Securities, Debt-551.00
Proceeds from other investments0.00
Upfrontandmilestonepaymentsrelatedtocollaborativeandotherarrangements-
Purchases of other investments0.00
Noncontrolling interest0.00
Proceeds from Investments0.00
Payments to Acquire Other Investments-35.00
Purchases of non-current assets0.00
Payments to Acquire Businesses, Net of Cash Acquired-11,318.00
Investment in affiliate0.00
Sale of businesses0.00
Proceeds from sale of assets0.00
Notes receivable0.00
Payments for (Proceeds from) Other Investing Activities3.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-8,577.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings1,302.00
Long-term debt - repayments0.00
Noncontrolling interest0.00
Issuances / -repurchases of Comm. Stock-599.00
Exercise of stock options0.00
Issuances / -repurchases of Pref. Stock0.00
Discontinued Operations0.00
Other financing activities net-529.00
Other net0.00
Payments To Acquire Convertible Note Hedges-
Proceeds From Debt Financing Net Of Issuance Costs-
Proceeds From Convertible Note Hedges-
Proceeds Payments Of Convertible Note Hedges-
Paymentto Settle Warrants Relatedto Convertible Notes-
Purchases Of Convertible Note Hedges-
Paymentofcontingentconsideration-
Purchasesofconvertiblenotehedgescashoutflow-
Dividends paid to minority interests0.00
Dividends paid-2,069.00
Net Cash Flow from Financing Activities-1,895.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow5,860.00
Total Cash Flow-4,385.00
4 historic quarters locked

Sign in to unlock the full Gilead Sciences Inc cash flow history.

Sign In Create Free Account

About Gilead Sciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000882095-26-000031

Figures are derived from filed reports and may be restated. Historical data is subject to revision.